Mondias receives positive results from greenhouse production tests conducted on CELEXT07 with leading cannabis producer
MONTREAL, March 18, 2019 /CNW/ – Mondias Naturals Inc. (“Mondias” or the “Company”) (TSXV: NHP) is pleased to announce the results of its greenhouse production tests conducted in collaboration with McGill University and a leading cannabis producer on its proprietary CELEXT07 bio-defense stimulant plant extract.
Mondias has been developing CELEXT07 to help prevent fungal growth on plants through its proven ability to boost plant defense systems. The objective of the tests was to measure the product’s efficacy in reducing and suppressing the most common fungal diseases encountered in cannabis through the application of CELEXT07 alone and in combination with a botanically-derived antimicrobial plant extract grown in greenhouse production systems.
Summary of the test results:
Preliminary results showed that foliar application of CELEXT07 alone resulted in the prevention of powdery mildew on cannabis leaves.
Foliar application of CELEXT07 combined with the tested botanically-derived antimicrobial plant extract resulted in the prevention and suppression of powdery mildew on the leaves of three commercial varieties of cannabis. This combination was the most effective in protecting the cannabis variety most susceptible to powdery mildew.
When applied alone or in combination with the tested botanically-derived antimicrobial plant extract as a foliar spray, CELEXT07 did not produce any phytotoxic effects on cannabis leaves.
Soil drench application of CELEXT07 helped suppress grey mould on hops, a close relative of cannabis.
“These results validate the effectiveness of CELEXT07’s bio-defense stimulant properties and open up a large potential market for Mondias, especially as the testing was done in collaboration with a leading cannabis producer,” said Jean-Philippe Gravel, Chief Executive Officer of Mondias. “Furthermore, cannabis growers are seeking eco-friendly alternatives to pesticides. The results from these greenhouse production tests will allow us to market CELEXT07 to a growing number of Canadian cannabis producers. The product is ready to market, and we have secured the production capacity we need to meet demand from potential clients.”
With post-harvest losses of one-third of the food produced worldwide for human consumption (Gastavsson et al., 2011) and annual economic losses of $10 billion to $100 billion worldwide due to grey mould and powdery mildew (L. Hua et al., 2018), the market potential for CELEXT07 is considerable.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health care, bio-agriculture and organic markets. The company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the success of this joint venture, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.